Department of Urology, China University of Mining and Technology, Xuzhou No.1 People's Hospital, Xuzhou, China.
Department of Hematopathology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Sci Rep. 2023 Apr 12;13(1):5935. doi: 10.1038/s41598-022-21447-2.
MicroRNAs play a critical regulatory role in different cancers, but their functions in renal cell carcinoma (RCC) have not been elucidated. Reportedly, miR-142-3p is involved in the tumorigenesis and the development of RCC in vitro and is clinically correlated with the poor prognosis of RCC patients. However, the molecular target of miR-142-3p and the underlying mechanism are unclear. In this study, we found that miR-142-3p was upregulated in RCC tumor tissues and downregulated in exosomes compared to normal tissues. The expression of miR-142-3p was inversely associated with the survival of patients with kidney renal clear cell carcinoma (KIRC). RhoBTB3 was reduced in RCC, and miR-142-3p plays an inverse function with RhoBTB3 in KIRC. The direct interaction between RhoBTB3 and miR-142-3p was demonstrated by a dual luciferase reporter assay. miR-142-3p promoted metastasis in the xenograft model, and the suppression of miR-142-3p upregulated RhoBTB3 protein expression and inhibited the mRNAs and proteins of HIF1A, VEGFA, and GGT1. Also, the miR-142-3p overexpression upregulated the mRNA of HIF1A, VEGFA, and GGT1. In conclusion, miR-142-3p functions as an oncogene in RCC, especially in KIRC, by targeting RhoBTB3 to regulate HIF-1 signaling and GGT/GSH pathways, which needs further exploration.
MicroRNAs 在不同癌症中发挥着关键的调节作用,但它们在肾细胞癌(RCC)中的功能尚未阐明。据报道,miR-142-3p 参与了 RCC 的体外发生和发展,并且与 RCC 患者的不良预后相关。然而,miR-142-3p 的分子靶标和潜在机制尚不清楚。在本研究中,我们发现 miR-142-3p 在 RCC 肿瘤组织中上调,而在正常组织中下调。miR-142-3p 的表达与肾透明细胞癌(KIRC)患者的生存呈负相关。RCC 中 RhoBTB3 减少,miR-142-3p 在 KIRC 中与 RhoBTB3 呈负相关。双荧光素酶报告基因检测证实了 RhoBTB3 与 miR-142-3p 的直接相互作用。miR-142-3p 在异种移植模型中促进转移,抑制 miR-142-3p 上调 RhoBTB3 蛋白表达,并抑制 HIF1A、VEGFA 和 GGT1 的 mRNAs 和蛋白。此外,miR-142-3p 的过表达上调了 HIF1A、VEGFA 和 GGT1 的 mRNA。总之,miR-142-3p 通过靶向 RhoBTB3 调节 HIF-1 信号和 GGT/GSH 途径,在 RCC 中发挥癌基因作用,特别是在 KIRC 中,这需要进一步探索。